{"id":"W2618666290","doi":"10.1016/j.pharmthera.2017.05.010","title":"Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer","year":2017,"lang":"en","type":"review","venue":"Pharmacology & Therapeutics","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Celldex Therapeutics; McGill University; U.S. Department of Defense","keywords":"Clinical trial; Medicine; Context (archaeology); Metastasis; Cancer; Antibody-drug conjugate; Cancer research; Oncology; Bioinformatics; Internal medicine; Pharmacology; Immunology; Biology; Monoclonal antibody; Antibody","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004203368,0.000591332,0.001075356,0.001049291,0.0001480595,0.0009187817,0.0006678508,0.0006598375,0.002847979],"category_scores_gemma":[0.0003549747,0.0001901359,0.0004404864,0.0009621148,0.0003312256,0.0009143597,0.0005040137,0.001745441,0.001350719],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004683051,"about_ca_system_score_gemma":0.0007258696,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007740853,"about_ca_topic_score_gemma":0.002354132,"domain_scores_codex":[0.9999063,0.00001289439,0.00001040427,0.00001437489,0.00003773972,0.00001828642],"domain_scores_gemma":[0.9998974,0.0000364465,0.00002031672,0.00000320607,0.00002933953,0.00001341411],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000166527,0.0001008571,0.0001766077,0.008785084,0.000113207,0.0001599931,0.00003676373,0.0003982353,0.004762826,0.004033784,0.02304255,0.9582235],"study_design_scores_gemma":[0.00009061373,0.0002036087,0.0006958696,0.001391824,0.0001807884,0.0009945732,0.0000356931,0.0002377189,0.001659781,0.00196834,0.9925207,0.00002049682],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004195681,0.997809,0.0002398305,0.0003944597,0.0001689085,0.00000686709,0.00002782583,0.00001321185,0.0009203969],"genre_scores_gemma":[0.001983445,0.996524,0.0002681533,0.0002708737,0.0001110033,0.000006673111,0.00005259722,0.000001793609,0.0007813947],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002847979,"threshold_uncertainty_score":0.009527385,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4104595518385268,"score_gpt":0.519545667675315,"score_spread":0.1090861158367881,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}